Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle triggered by
volatile anesthetics or succinylcholine. It manifests as a potentially lethal hypermetabolic …

With migration of medically complex patients undergoing more extensive surgical
procedures to the ambulatory setting, selecting the appropriate patient is vital. Patient …

Malignant hyperthermia is defined in the International Classification of Diseases as a
progressive life‐threatening hyperthermic reaction occurring during general anaesthesia …

Survival from a malignant hyperthermia (MH) crisis is highly dependent on early recognition
and prompt action. MH crises are very rare and an increasing use of total iv anaesthesia is …

BACKGROUND: Between 1992 and 2011, 373 Canadian individuals with adverse
anesthetic reaction were referred to the Malignant Hyperthermia Unit in Toronto, Ontario …

Background The safety of bilateral total knee arthroplasties (BTKA) during the same
hospitalization remains controversial. We sought to study differences in perioperative …

BACKGROUND: Malignant hyperthermia (MH) is a pharmacogenetic syndrome that variably
expresses itself on exposure to triggering agents. MH prevalence in the United States is not …

The identification in a patient of 1 of the 50 variants in the RYR 1 or CACNA 1S genes
reviewed here should lead to a presumption of malignant hyperthermia susceptibility (MHS) …

Purpose This continuing professional development module aims to prepare
anesthesiologists for the timely recognition and management of a malignant hyperthermia …

Malignant hyperthermia susceptibility (MHS) is a pharmacogenetic disorder of skeletal
muscle calcium regulation associated with uncontrolled skeletal muscle hypermetabolism …